 |
|
|
| |
A Once-per-week or Every-two-week Dosing Regimen is More Efficacious for the TLR7 Agonist JNJ-64794964 (JNJ-4964) to Induce an Anti-hepatitis B Virus (HBV) Effect
and HBV-specific Immune Responses in AAV-HBV Mice
|
| |
| |
EASL 2020 Aug 27-29 virtual
Reported by Jules Levin
Florence Herschke1, Chris Li2,*, Ren Zhu2, Qinglin Han2, Qun Wu2, Qing Lu2, Tse-I Lin3,*, An De Creus1
1Janssen Pharmaceutica NV, Beerse, Belgium; 2Asia Pacific Centre of Excellence of Translational Science, Shanghai, China; 3Janssen South San Francisco, CA, USA
*No longer with Janssen
|
| |
|
|
|
|
|
